Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY | Market Cap | 8.40T +32.6% |
| Revenue (ttm) | 4.51T -1.7% |
| Net Income | 191.76B +77.7% |
| EPS | 119.64 +78.0% |
| Shares Out | 1.58B |
| PE Ratio | 44.47 |
| Forward PE | 38.96 |
| Dividend | 204.00 (3.93%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 5,258,600 |
| Average Volume | 4,175,315 |
| Open | 5,256.00 |
| Previous Close | 5,256.00 |
| Day's Range | 5,252.00 - 5,327.00 |
| 52-Week Range | 4,035.00 - 6,033.00 |
| Beta | n/a |
| RSI | 41.28 |
| Earnings Date | May 13, 2026 |
About TYO:4502
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Repla... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2026, TYO:4502's revenue was 4.51 trillion, a decrease of -1.66% compared to the previous year's 4.58 trillion. Earnings were 191.76 billion, an increase of 77.68%.
Financial StatementsNews
Justice Department announces $13.67M civil settlement with Takeda
The Department of Justice said Takeda (TAK) Pharmaceuticals has agreed to pay $13.67M to resolve allegations that it “knowingly caused the submission of false claims to Medicare and other federal…
Takeda Pharmaceutical (TAK) Announces Global Restructuring with Job Cuts
Takeda Pharmaceutical (TAK) Announces Global Restructuring with Job Cuts
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
Japan's Takeda Pharmaceutical , plans to cut about 4,500 jobs in fiscal year 2026, as it pushes ahead with a restructuring to centralize corporate functions and reduce costs.
Takeda (TAK) Preserved FY2025 Margins, but FY2026 Now Depends on the Launch Pipeline
Takeda Pharmaceutical (TAK) delivered what investors needed from fiscal 2025: enough cost control and cash generation to offset a tougher... The post Takeda (TAK) Preserved FY2025 Margins, but FY2026 ...
Takeda Pharmaceutical Company Earnings Call Transcript: Q4 2026
FY 2025 saw resilient financials despite VYVANSE LOE, with core revenue at JPY 4.5T and strong cash flow. Three late-stage assets are set for launch, supporting a new growth phase, while a transformation program aims to boost efficiency and margins.
Takeda Pharmaceutical (TAK) Reports FY Non-GAAP EPS of ¥517.00 Amid Revenue Decline
Takeda Pharmaceutical (TAK) Reports FY Non-GAAP EPS of ¥517.00 Amid Revenue Decline
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with i...
Takeda Pharmaceutical Announces Positive Data From TAK-881 Trial
(RTTNews) - Monday, Takeda Pharmaceutical Company Limited (TAK) announced positive topline data from TAK-881-3001, a pivotal Phase 2/3 clinical trial evaluating TAK-881 in patients with Primary Immuno...
Takeda announces TAK-881-3001 trial in PID met primary endpoint
Takeda (TAK) announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease, met its primary endpoint, which demonstrated pharmacokinetic comparabili...
Takeda's immune disease drug meets main goal of mid-to-late stage trial
Takeda Pharmaceutical said its experimental drug for primary immunodeficiency disease, a rare condition that weakens the immune system, has met the main goal of a mid- to late-stage cli...
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.
Takeda Pharmaceutical Enters Oversold Territory (TAK)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight
The polycythemia vera market is set for expansion by 2036, as new entrants such as Protagonist Therapeutics and Takeda Pharmaceuticals (rusfertide), Merck (bomedemstat), Italfarmaco (givinostat), Ioni...
Takeda upgraded to Outperform from Market Perform at Bernstein
Bernstein upgraded Takeda (TAK) to Outperform from Market Perform with a price target of 6,900 yen, up from 5,100 yen, citing “bold” cost cuts and multiple upcoming de-risking events for
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Takeda on Friday notified Denali Therapeutics regarding the termination of their collaboration agreement to co-develop DNL593, a progranulin replacement therapy for frontotemporal dementia.
Denali Therapeutics regains full rights to DNL593
Denali Therapeutics (DNLI) announced that it has received notification from Takeda (TAK) of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commerc...
Takeda announces new data from Phase 3 studies of TAK-279
Takeda (TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib, TAK-279, a next-generation, highly selective oral tyrosine kinase 2 inhibitor, in adults with moderate-to-severe pl...
Takeda Pharmaceutical Company Transcript: Study Update
Phase III studies show zasocitinib delivers rapid, durable skin clearance and significant quality-of-life improvements for moderate-to-severe plaque psoriasis, outperforming apremilast and placebo. The once-daily oral therapy demonstrated a strong safety profile and is positioned to expand the oral psoriasis market.
Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care.
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Takeda Pharmaceutical Company Transcript: TD Cowen 46th Annual Health Care Conference
Three NMEs are set for launch following strong phase III results, with a new CEO transition and a focus on digital transformation. Oveporexton, zasocitinib, and rusfertide each target distinct markets with robust efficacy and safety profiles, while pipeline expansion and new indications are planned.
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
Takeda (TAK) and Protagonist Therapeutics (PTGX) announced that the FDA accepted the new drug application and granted priority review for rusfertide. Rusfertide is an investigational hepcidin mimetic ...
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Dr...
Takeda announces data from Phase 3 KEPLER trial of ENTYVIO
Takeda (TAK) announced data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO can offer the possibility of clinical remission for patients ages 2 and older with moderately
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can off...